I kliniske forsøg er der observeret alvorlige infektioner i forbindelse med samtidig administration af anakinra og en anden TNF- antagonist, etanercept, uden yderligere klinisk virkning end ved anvendelse af etanercept alene.
Serious infections were seen in clinical studies with concurrent use of anakinra and another TNF-antagonist, etanercept, with no added clinical benefit compared to etanercept alone.